Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823124 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1L3MBTL1ALOX5FAAH | |
| SCHEMBL6077517 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1L3MBTL1ALOX5FAAH | |
| SCHEMBL1357622 | 0.88 | TP53 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL27156506 | 0.88 | TP53 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL10126870 | 0.85 | KMT2A (0.42) | ALDH1A1ALOX5KMT2A | |
| SCHEMBL18045294 | 0.85 | KMT2A (0.42) | ALDH1A1ALOX5KMT2A | |
| SCHEMBL12344914 | 0.82 | ALOX5 (0.41) | ALOX5KMT2A | |
| SCHEMBL13624815 | 0.82 | ALOX5 (0.41) | ALOX5KMT2A | |
| SCHEMBL18076669 | 0.80 | KMT2A (0.41) | ALDH1A1ALOX5KMT2A | |
| SCHEMBL6823126 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | ALDH1A1 2954/4885MAPK1 1399/4885L3MBTL1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.